Sanai, F.M.; Odah, H.O.; Alshammari, K.; Alzanbagi, A.; Alsubhi, M.; Tamim, H.; Alolayan, A.; Alshehri, A.; Alqahtani, S.A.
Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers 2024, 16, 2196.
https://doi.org/10.3390/cancers16122196
AMA Style
Sanai FM, Odah HO, Alshammari K, Alzanbagi A, Alsubhi M, Tamim H, Alolayan A, Alshehri A, Alqahtani SA.
Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers. 2024; 16(12):2196.
https://doi.org/10.3390/cancers16122196
Chicago/Turabian Style
Sanai, Faisal M., Hassan O. Odah, Kanan Alshammari, Adnan Alzanbagi, Murooj Alsubhi, Hani Tamim, Ashwaq Alolayan, Ahmed Alshehri, and Saleh A. Alqahtani.
2024. "Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma" Cancers 16, no. 12: 2196.
https://doi.org/10.3390/cancers16122196
APA Style
Sanai, F. M., Odah, H. O., Alshammari, K., Alzanbagi, A., Alsubhi, M., Tamim, H., Alolayan, A., Alshehri, A., & Alqahtani, S. A.
(2024). Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 16(12), 2196.
https://doi.org/10.3390/cancers16122196